Reblozyl (luspatercept-aamt) / BMS, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   40 Trials   40 Trials   1659 News 


«12...6789101112131415161718»
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Journal:  Therapy for lower-risk MDS. (Pubmed Central) -  May 11, 2021   
    The presence of pancytopenia and or intensifying and unremitting clinical symptoms are often treated with hypomethylating agents or (anti-thymocyte globulin if hypocellular MDS is of concern). Targeted therapies are emerging for small subsets of MDS patients with specific somatic mutations (ie, TP53, IDH1/2, FLT3), although currently, there are no approved, mutation-directed medications to treat MDS.
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Journal:  Myelodysplastic syndromes: moving towards personalized management. (Pubmed Central) -  Apr 28, 2021   
    However, recent studies show increased cure rates due to better tools to target the malignant clone with less toxicity. This review provides a comprehensive overview of the current status of the clinical evaluation, biology and therapeutic interventions for this spectrum of disorders.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Clinical, Review, Journal:  Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review. (Pubmed Central) -  Apr 20, 2021   
    Based on the conducted studies, the effectiveness of luspatercept on transfusion burden and hemoglobin levels was outstanding in β-thalassemia patients. Further large and well-designed clinical studies are needed to identify any unforeseen complications subsequent to use of luspatercept, particularly when used with other treatments with potentially serious adverse effects such as anti-osteoporotic and iron chelator agents.
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Review, Journal:  Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. (Pubmed Central) -  Apr 7, 2021   
    While there have been no FDA-approved therapies for MDS in the past decade, we anticipate the approval of luspatercept based on results from the MEDALIST trial for patients with lower-risk MDS (MDS-LR) and ringed sideroblasts who have failed or are ineligible for erythropoiesis stimulating agents (ESAs). With growing knowledge of the biologic and molecular mechanisms underlying MDS, it is anticipated that new therapies will be approved in the coming years.
  • ||||||||||  decitabine / Generic mfg.
    Clinical, Review, Journal:  Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). (Pubmed Central) -  Apr 7, 2021   
    Although early results from novel molecularly driven agents such as IDH1/2 inhibitors, venetoclax, magrolimab, and APR-246 for MDS as well as tagraxofusp, tipifarnib, and lenzilumab for CMML appear encouraging, confirmatory randomized trials must be completed to fully assess their safety and efficacy prior to routine clinical use. Herein, we review the current management of MDS and CMML and conclude with a critical appraisal of novel therapies and general trends in this field.
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Enrollment change, Trial completion date, Trial primary completion date:  AZA-MDS-006: Connect (clinicaltrials.gov) -  Apr 1, 2021   
    P=N/A,  N=2900, Recruiting, 
    Herein, we review the current management of MDS and CMML and conclude with a critical appraisal of novel therapies and general trends in this field. N=2100 --> 2900 | Trial completion date: Dec 2030 --> Mar 2031 | Trial primary completion date: Dec 2022 --> Mar 2031
  • ||||||||||  [VIRTUAL] A Conversation with the Investigators: Acute Myeloid Leukemia and Myelodysplastic Syndromes () -  Mar 12, 2021 - Abstract #ASCO2021ASCO_174;    
    Describe the biologic rationale for and mechanism of action of luspatercept in the treatment of anemia secondary to MDS, and appraise how this agent can be appropriately integrated into clinical practice. Recall promising agents and combination strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Review, Journal:  Luspatercept in Myelodysplastic Syndromes: Who and When? (Pubmed Central) -  Feb 23, 2021   
    This article reviews the mechanism of impaired erythropoiesis in MDS. It summarizes clinical data with luspatercept and foresees how to best use this treatment in practice.
  • ||||||||||  sotatercept (ACE-011) / Acceleron, BMS, Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Journal:  Emerging therapies in β-Thalassemia: towards a new era in management. (Pubmed Central) -  Feb 4, 2021   
    Advances in understanding the underlying pathophysiology of β-thalassemia enabled clinicians and researchers to move towards the development of novel therapeutic modalities. These can be classified into three categories based on their efforts to address different features of the underlying pathophysiology of β-thalassemia: correction of the globin chain imbalance, addressing ineffective erythropoiesis, and improving iron overload.Areas covered: In this review, we will provide an overview of the novel therapeutic approaches that are currently in development for β-thalassemia.Expert opinion: A thorough understanding of the pathophysiology and overall disease burden of β-thalassemia has aided clinicians and scientists to optimize disease management approaches and construct a plan for the development of novel therapies, with ultimate goals of prolonging longevity, reducing symptom burden, improving compliance and adherence for a better quality of life.
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Review, Journal:  Treatment options for lower-risk myelodysplastic syndromes. Where are we now? (Pubmed Central) -  Jan 29, 2021   
    While anemia is the most common cytopenia, thrombocytopenia and neutropenia management is challenging and the co-occurrence of these cytopenias with anemia may dictate the choice of therapy. In this article, we review LR-MDS and discuss the optimal use of current treatment options and explore new therapeutic options on the horizon.
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Clinical, Review, Journal:  How we manage adults with myelodysplastic syndrome. (Pubmed Central) -  Jan 26, 2021   
    The role of new drugs, including venetoclax or, in case of specific mutations, IDH1 or IDH2 inhibitors, is investigated. IC is mainly indicated as a bridge to allo-SCT, in the absence of unfavourable karyotype.
  • ||||||||||  Journal:  Investigational non-JAK inhibitors for chronic phase myelofibrosis. (Pubmed Central) -  Jan 21, 2021   
    Drugs that target new molecular pathways (MDM2, p-selectin, TIM-3, Bcl-2, TGF-β, aurora kinase) and immune-based strategies (CALR vaccine, anti-PD-1, allogeneic cord blood regulatory T cells) are in early phase trials. Further translational studies to target leukemic stem cells, improvement in trial designs by incorporating control arm and survival endpoints, and patient-focused collaborations among all stakeholders could pave a way for future success in MF drug development.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Clinical, Journal, CME:  An assessment of the continuing medical education needs of US physicians in the management of patients with beta thalassemia. (Pubmed Central) -  Jan 14, 2021   
    Physicians in CoEs as compared with non-CoE physicians reported greater knowledge of beta thalassemia and familiarity with butyrates, gene therapy, and luspatercept...Differences CoE vs non-CoE physician responses suggest variations in knowledge, practice, and attitudes that may be helpful in tailoring CME activities to different learner audiences. The small sample size used in some sub-analyses may not be representative of all hematologists treating beta thalassemia patients.
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    Journal:  Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. (Pubmed Central) -  Jan 12, 2021   
    We discuss how alternative therapies could benefit patients with chronic myeloid leukemia (CML) who develop BCR-ABL1 mutant subclones following ABL1-tyrosine kinase inhibitor therapy (TKIs). In MPNs, we focus on efforts beyond JAK-STAT and the merits of integrating activin receptor ligand traps, interferon-α, and allografting in the current treatment algorithm for patients with myelofibrosis (MF).
  • ||||||||||  Reblozyl (luspatercept-aamt) / Acceleron, BMS
    [VIRTUAL] Effects of luspatercept on iron overload and impact on responders to luspatercept: results from the BELIEVE Trial () -  Jan 5, 2021 - Abstract #BSHI2020BSH-I_99;    
    P3
    Luspatercept treatment resulted in statistically significant reductions in serum ferritin, and there was a trend for decrease in liver iron concentration. These data suggest that luspatercept may contribute to improved control of body iron in patients with beta‐thalassaemia who require regular RBC transfusions, particularly in those achieving at least a 33% reduction in RBC transfusion burden.
  • ||||||||||  Revlimid (lenalidomide) / BMS, Reblozyl (luspatercept-aamt) / Acceleron, BMS, Inqovi (decitabine/cedazuridine) / Otsuka
    Journal:  Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management. (Pubmed Central) -  Dec 31, 2020   
    At the present time there are no approved interventions for patients with progressive or refractory disease particularly after HMA based therapy. Options include participation in a clinical trial or cytarabine based therapy or alloSCT.